CN101287497A - 涂层脂质复合体和它们的用途 - Google Patents
涂层脂质复合体和它们的用途 Download PDFInfo
- Publication number
- CN101287497A CN101287497A CNA2005800450816A CN200580045081A CN101287497A CN 101287497 A CN101287497 A CN 101287497A CN A2005800450816 A CNA2005800450816 A CN A2005800450816A CN 200580045081 A CN200580045081 A CN 200580045081A CN 101287497 A CN101287497 A CN 101287497A
- Authority
- CN
- China
- Prior art keywords
- lipid
- compositions
- lipid composition
- group
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 284
- 239000000203 mixture Substances 0.000 claims abstract description 293
- 150000001875 compounds Chemical class 0.000 claims abstract description 130
- 238000001727 in vivo Methods 0.000 claims abstract description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 97
- 108020004707 nucleic acids Proteins 0.000 claims description 97
- 150000007523 nucleic acids Chemical class 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 65
- -1 cation lipid Chemical class 0.000 claims description 51
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 41
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 41
- 229940106189 ceramide Drugs 0.000 claims description 41
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 41
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 41
- 108020004459 Small interfering RNA Proteins 0.000 claims description 36
- GGYKPYDKXLHNTI-UHFFFAOYSA-N 2,6,10,14-tetramethylhexadecane Chemical compound CCC(C)CCCC(C)CCCC(C)CCCC(C)C GGYKPYDKXLHNTI-UHFFFAOYSA-N 0.000 claims description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 108091030071 RNAI Proteins 0.000 claims description 27
- 230000009368 gene silencing by RNA Effects 0.000 claims description 27
- 244000089409 Erythrina poeppigiana Species 0.000 claims description 24
- 235000009776 Rathbunia alamosensis Nutrition 0.000 claims description 24
- 101150054147 sina gene Proteins 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 102000053642 Catalytic RNA Human genes 0.000 claims description 18
- 108090000994 Catalytic RNA Proteins 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 108091092562 ribozyme Proteins 0.000 claims description 18
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Norphytane Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims description 16
- 230000003044 adaptive effect Effects 0.000 claims description 16
- 125000000129 anionic group Chemical group 0.000 claims description 16
- 229940113162 oleylamide Drugs 0.000 claims description 16
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 235000018102 proteins Nutrition 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 150000007513 acids Chemical class 0.000 claims description 12
- 102000053602 DNA Human genes 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- BKHMAOXOKNEKHL-NNJYRKLXSA-N (5s)-2,3,5-triamino-8-(diaminomethylideneamino)-n-hexadecyl-n-[(z)-octadec-9-enyl]-4-oxooctanamide;trihydrochloride Chemical compound Cl.Cl.Cl.CCCCCCCCCCCCCCCCN(C(=O)C(N)C(N)C(=O)[C@@H](N)CCCNC(N)=N)CCCCCCCC\C=C/CCCCCCCC BKHMAOXOKNEKHL-NNJYRKLXSA-N 0.000 claims description 8
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 8
- 150000001450 anions Chemical class 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 210000001163 endosome Anatomy 0.000 claims description 8
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000035945 sensitivity Effects 0.000 claims description 8
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 150000003431 steroids Chemical class 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 6
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 229960003330 pentetic acid Drugs 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- GGZUDCAITXWZKO-VQJSHJPSSA-N PE(O-18:0/O-18:0) Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCCCCCCCCCCCC GGZUDCAITXWZKO-VQJSHJPSSA-N 0.000 claims description 3
- 108091081021 Sense strand Proteins 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 238000006384 oligomerization reaction Methods 0.000 claims description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 83
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 229920001223 polyethylene glycol Polymers 0.000 description 38
- 239000002502 liposome Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000002552 dosage form Substances 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 17
- 229910052786 argon Inorganic materials 0.000 description 14
- 230000002194 synthesizing effect Effects 0.000 description 13
- 208000035126 Facies Diseases 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- CHAQTRWDLCZRSS-ZPHPHTNESA-N (z)-n-hexadecyloctadec-9-en-1-amine Chemical compound CCCCCCCCCCCCCCCCNCCCCCCCC\C=C/CCCCCCCC CHAQTRWDLCZRSS-ZPHPHTNESA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 238000000265 homogenisation Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910052756 noble gas Inorganic materials 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- BGOFOVHACSQSIE-ZDUSSCGKSA-N (2s)-5-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCNC(NC(=O)OC(C)(C)C)=NC(=O)OC(C)(C)C BGOFOVHACSQSIE-ZDUSSCGKSA-N 0.000 description 4
- WHCIIBFQTPHINC-UHFFFAOYSA-N 9H-fluoren-9-ylmethyl 15-(dodecylamino)pentadecanoate Chemical compound C1=CC=C2C(COC(=O)CCCCCCCCCCCCCCNCCCCCCCCCCCC)C3=CC=CC=C3C2=C1 WHCIIBFQTPHINC-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- VHAZCTYLSXXYPK-YKOZOZHESA-N (2S,8S)-2,6,8-triamino-11-(diaminomethylideneamino)-N-dodecyl-7-oxo-N-tetradecylundecanamide trihydrochloride Chemical compound Cl.Cl.Cl.CCCCCCCCCCCCCCN(CCCCCCCCCCCC)C(=O)[C@@H](N)CCCC(N)C(=O)[C@@H](N)CCCNC(N)=N VHAZCTYLSXXYPK-YKOZOZHESA-N 0.000 description 3
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229910010082 LiAlH Inorganic materials 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229940124447 delivery agent Drugs 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical group CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MVWPBNQGEGBGRF-IBGZPJMESA-N (2s)-3-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2C(COC(=O)NC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 MVWPBNQGEGBGRF-IBGZPJMESA-N 0.000 description 2
- MDCPCLPRWLKUIQ-LURJTMIESA-N (2s)-4-azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C([O-])=O)CC[NH3+] MDCPCLPRWLKUIQ-LURJTMIESA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- IVZSTQJPMCJHFE-ZPHPHTNESA-N (z)-n-hexadecyloctadec-9-enamide Chemical compound CCCCCCCCCCCCCCCCNC(=O)CCCCCCC\C=C/CCCCCCCC IVZSTQJPMCJHFE-ZPHPHTNESA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- GTXFAULFJGSXIZ-KHPPLWFESA-N CCCCCCCCCCCCCCCCNCCCCCCCC/C=C\CCCCCCCCC(OCC1C2=CC=CC=C2C2=CC=CC=C12)=O Chemical compound CCCCCCCCCCCCCCCCNCCCCCCCC/C=C\CCCCCCCCC(OCC1C2=CC=CC=C2C2=CC=CC=C12)=O GTXFAULFJGSXIZ-KHPPLWFESA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- MZKSBYBYCXBNGA-UHFFFAOYSA-N n-dodecyltetradecan-1-amine Chemical compound CCCCCCCCCCCCCCNCCCCCCCCCCCC MZKSBYBYCXBNGA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- DNQLZTCMXBGQRX-ULVNQHIKSA-N (2S,8S)-2,6,8-triamino-11-(diaminomethylideneamino)-N-dodecyl-7-oxo-N-tetradecylundecanamide Chemical compound CCCCCCCCCCCCCCN(CCCCCCCCCCCC)C(=O)[C@@H](N)CCCC(N)C(=O)[C@@H](N)CCCNC(N)=N DNQLZTCMXBGQRX-ULVNQHIKSA-N 0.000 description 1
- JYEVQYFWINBXJU-QFIPXVFZSA-N (2s)-6-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JYEVQYFWINBXJU-QFIPXVFZSA-N 0.000 description 1
- GSWOSWNLZJKHMV-NVVYMUDLSA-N (5s)-2,3,5-triamino-8-(diaminomethylideneamino)-n-dodecyl-4-oxo-n-tetradecyloctanamide Chemical compound CCCCCCCCCCCCCCN(C(=O)C(N)C(N)C(=O)[C@@H](N)CCCN=C(N)N)CCCCCCCCCCCC GSWOSWNLZJKHMV-NVVYMUDLSA-N 0.000 description 1
- OEMCZAYGMXQWMX-ZBTGGCOQSA-N (5s)-2,3,5-triamino-8-(diaminomethylideneamino)-n-hexadecyl-n-[(z)-octadec-9-enyl]-4-oxooctanamide Chemical compound CCCCCCCCCCCCCCCCN(C(=O)C(N)C(N)C(=O)[C@@H](N)CCCN=C(N)N)CCCCCCCC\C=C/CCCCCCCC OEMCZAYGMXQWMX-ZBTGGCOQSA-N 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- HNTGIJLWHDPAFN-UHFFFAOYSA-N 1-bromohexadecane Chemical compound CCCCCCCCCCCCCCCCBr HNTGIJLWHDPAFN-UHFFFAOYSA-N 0.000 description 1
- KOFZTCSTGIWCQG-UHFFFAOYSA-N 1-bromotetradecane Chemical compound CCCCCCCCCCCCCCBr KOFZTCSTGIWCQG-UHFFFAOYSA-N 0.000 description 1
- SODQFLRLAOALCF-UHFFFAOYSA-N 1lambda3-bromacyclohexa-1,3,5-triene Chemical compound Br1=CC=CC=C1 SODQFLRLAOALCF-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BGZMXIBOPNTHJS-BZKIHGKGSA-N CCCCCCCC/C=C\CCCCCCCCN.Cl.Cl.Cl Chemical compound CCCCCCCC/C=C\CCCCCCCCN.Cl.Cl.Cl BGZMXIBOPNTHJS-BZKIHGKGSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N trifluoromethane acid Natural products FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
阳离子脂质[摩尔%] | DPhyPE[摩尔%] | C8mPEG2000[摩尔%] | |
A1 | 50摩尔% | 49 | 1 |
A2 | 50摩尔% | 47.5 | 2.5 |
A3 | 50摩尔% | 45.0 | 5.0 |
A4 | 50摩尔% | 42.5 | 7.5 |
A5 | 50摩尔% | 40.0 | 10 |
Cationic lipid[摩尔%] | DPhyPE[摩尔%] | C8mPEG2000[摩尔%] | |
B1 | 49 | 50摩尔% | 1 |
B2 | 47.5 | 50摩尔% | 2.5 |
B3 | 45.0 | 50摩尔% | 5.0 |
B4 | 42.5 | 50摩尔% | 7.5 |
B5 | 40 | 50摩尔% | 10.0 |
Claims (55)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04030846.2 | 2004-12-24 | ||
EP04030846 | 2004-12-27 | ||
PCT/EP2005/014074 WO2006069782A2 (en) | 2004-12-27 | 2005-12-27 | Lipid complexes coated with peg and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101287497A true CN101287497A (zh) | 2008-10-15 |
CN101287497B CN101287497B (zh) | 2013-03-06 |
Family
ID=36540272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800450816A Expired - Fee Related CN101287497B (zh) | 2004-12-27 | 2005-12-27 | 涂层脂质复合体和它们的用途 |
Country Status (17)
Country | Link |
---|---|
US (2) | US8852472B2 (zh) |
EP (2) | EP2992902A1 (zh) |
JP (1) | JP5292572B2 (zh) |
KR (1) | KR101366482B1 (zh) |
CN (1) | CN101287497B (zh) |
AU (1) | AU2005321469B2 (zh) |
BR (1) | BRPI0519468A2 (zh) |
CA (1) | CA2593032C (zh) |
DK (1) | DK1830888T3 (zh) |
ES (1) | ES2548515T3 (zh) |
HK (2) | HK1119090A1 (zh) |
IL (1) | IL183775A (zh) |
MX (1) | MX2007007913A (zh) |
PL (1) | PL1830888T3 (zh) |
SG (1) | SG158175A1 (zh) |
WO (1) | WO2006069782A2 (zh) |
ZA (1) | ZA200704168B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105832709A (zh) * | 2016-03-14 | 2016-08-10 | 苏州博创康源生物技术有限公司 | 一种核酸药物载药组织粘贴膜及其制备方法 |
CN105873568A (zh) * | 2013-12-05 | 2016-08-17 | 赛伦斯治疗有限公司 | 用于肺特异性递送的工具 |
CN105902522A (zh) * | 2016-03-14 | 2016-08-31 | 苏州博创康源生物技术有限公司 | 一种蛋白或多肽药物载药组织粘贴膜及其制备方法 |
CN105902523A (zh) * | 2016-03-14 | 2016-08-31 | 苏州博创康源生物技术有限公司 | 一种载药组织粘贴膜及其制备方法 |
CN106038516A (zh) * | 2016-03-14 | 2016-10-26 | 苏州博创康源生物技术有限公司 | 一种化合物药物载药组织粘贴膜及其制备方法 |
CN106038517A (zh) * | 2016-03-14 | 2016-10-26 | 苏州博创康源生物技术有限公司 | 一种多糖药物载药组织粘贴膜及其制备方法 |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0313202A8 (pt) | 2002-08-05 | 2016-08-16 | Atugen Ag | Formas adicionais para interferir com as moléculas de rna |
WO2005105152A2 (en) | 2004-05-05 | 2005-11-10 | Atugen Ag | Lipids, lipid complexes and use thereof |
WO2006069782A2 (en) | 2004-12-27 | 2006-07-06 | Silence Therapeutics Ag. | Lipid complexes coated with peg and their use |
SG161311A1 (en) * | 2005-05-04 | 2010-05-27 | Noxxon Pharma Ag | Novel use of spiegelmers |
WO2007121947A1 (en) * | 2006-04-20 | 2007-11-01 | Silence Therapeutics Ag. | Lipoplex formulations for specific delivery to vascular endothelium |
RU2553561C2 (ru) * | 2006-07-21 | 2015-06-20 | Сайленс Терапьютикс Аг | Средства ингибирования экспрессии протеинкиназы 3 |
WO2008074487A2 (en) | 2006-12-19 | 2008-06-26 | Novosom Ag | Lipids and lipid assemblies comprising transfection enhancer elements |
WO2010021718A1 (en) | 2008-08-19 | 2010-02-25 | Nektar Therapeutics | Complexes of small-interfering nucleic acids |
JP2012517815A (ja) | 2009-02-18 | 2012-08-09 | サイレンス・セラピューティクス・アーゲー | Ang2の発現を阻害するための手段 |
WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
US8359883B2 (en) * | 2009-11-13 | 2013-01-29 | Hasmukh Dholakiya | Gemstone setting |
WO2011120053A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
WO2011133658A1 (en) | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
WO2012113413A1 (en) * | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
TW201408625A (zh) | 2012-07-06 | 2014-03-01 | Kyowa Hakko Kirin Co Ltd | 陽離子性脂質 |
WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
JP6896421B2 (ja) | 2013-08-21 | 2021-06-30 | キュアバック アーゲー | 呼吸器合胞体ウイルス(rsv)ワクチン |
US10611664B2 (en) | 2014-07-31 | 2020-04-07 | Corning Incorporated | Thermally strengthened architectural glass and related systems and methods |
US11097974B2 (en) | 2014-07-31 | 2021-08-24 | Corning Incorporated | Thermally strengthened consumer electronic glass and related systems and methods |
WO2016083623A1 (en) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for the treatment of pre-eclampsia |
KR101952085B1 (ko) | 2016-01-12 | 2019-05-21 | 코닝 인코포레이티드 | 얇은, 열적 및 화학적으로 강화된 유리-계 제품 |
US11795102B2 (en) | 2016-01-26 | 2023-10-24 | Corning Incorporated | Non-contact coated glass and related coating system and method |
CN110114461A (zh) | 2016-08-17 | 2019-08-09 | 博德研究所 | 新型crispr酶和系统 |
CN110312799A (zh) | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和系统 |
WO2019040818A2 (en) | 2017-08-24 | 2019-02-28 | Corning Incorporated | GLASSES HAVING ENHANCED TEMPERATURE CAPABILITIES |
KR20200066616A (ko) | 2017-09-21 | 2020-06-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
TWI785156B (zh) | 2017-11-30 | 2022-12-01 | 美商康寧公司 | 具有高熱膨脹係數及對於熱回火之優先破裂行為的非離子交換玻璃 |
US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
JP2021532815A (ja) | 2018-08-07 | 2021-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新規Cas12b酵素およびシステム |
WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
KR20210154825A (ko) | 2019-04-23 | 2021-12-21 | 코닝 인코포레이티드 | 확정 응력 프로파일을 갖는 유리 라미네이트 및 그 제조방법 |
WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
WO2021016075A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
CN114514115B (zh) | 2019-08-06 | 2023-09-01 | 康宁股份有限公司 | 具有用于阻止裂纹的埋入式应力尖峰的玻璃层压体及其制造方法 |
IL296660A (en) | 2020-03-24 | 2022-11-01 | Generation Bio Co | Non-viral DNA vectors and their use for therapeutic expression of factor ix |
MX2022011806A (es) | 2020-03-24 | 2023-01-11 | Generation Bio Co | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher. |
CN116322760A (zh) | 2020-05-20 | 2023-06-23 | 旗舰创业创新第六有限责任公司 | 冠状病毒抗原组合物及其用途 |
CN116194139A (zh) | 2020-05-20 | 2023-05-30 | 旗舰创业创新第六有限责任公司 | 免疫原性组合物及其用途 |
EP4158032A2 (en) | 2020-05-29 | 2023-04-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and methods relating thereto |
MX2022015042A (es) | 2020-05-29 | 2023-03-09 | Flagship Pioneering Innovations Vi Llc | Composiciones de trem y métodos relacionados con las mismas. |
KR20230056669A (ko) | 2020-07-27 | 2023-04-27 | 안자리움 바이오사이언시스 아게 | Dna 분자의 조성물, 이의 제조 방법 및 이의 사용 방법 |
CA3193746A1 (en) | 2020-09-03 | 2022-03-10 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
CA3206285A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
AU2022260111A1 (en) | 2021-04-20 | 2023-11-30 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
WO2022232286A1 (en) | 2021-04-27 | 2022-11-03 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
WO2022232289A1 (en) | 2021-04-27 | 2022-11-03 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
CN113372226B (zh) * | 2021-06-08 | 2023-05-26 | 深圳市人民医院 | 一种脂质分子、脂质纳米粒及其制备方法和应用 |
US20240336945A1 (en) | 2021-07-26 | 2024-10-10 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
AR127073A1 (es) | 2021-09-17 | 2023-12-13 | Flagship Pioneering Innovations Vi Llc | Composiciones y métodos para producir polirribonucleótidos circulares |
MX2024004618A (es) | 2021-10-18 | 2024-07-12 | Flagship Pioneering Innovations Vi Llc | Composiciones y metodos para purificar polirribonucleotidos. |
EP4430024A1 (en) | 2021-11-08 | 2024-09-18 | Orna Therapeutics, Inc. | Lipid nanoparticle compositions for delivering circular polynucleotides |
MX2024006407A (es) | 2021-11-24 | 2024-08-19 | Flagship Pioneering Innovations Vi Llc | Composiciones de inmunogenos del virus varicela-zoster y sus usos. |
EP4436984A1 (en) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
IL312965A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
MX2024007307A (es) | 2021-12-17 | 2024-08-06 | Flagship Pioneering Innovations Vi Llc | Métodos de enriquecimiento de arn circular en condiciones desnaturalizantes. |
AU2022417517A1 (en) | 2021-12-22 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
TW202342064A (zh) | 2021-12-23 | 2023-11-01 | 美商旗艦先鋒創新有限責任公司 | 編碼抗融合多肽之環狀多核糖核苷酸 |
WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
WO2023177655A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
AU2023239151A1 (en) | 2022-03-25 | 2024-10-03 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
WO2023220729A2 (en) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Double stranded dna compositions and related methods |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
WO2024030856A2 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024049979A2 (en) | 2022-08-31 | 2024-03-07 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
TW202425959A (zh) | 2022-11-08 | 2024-07-01 | 美商歐納醫療公司 | 遞送多核苷酸的脂質及奈米顆粒組合物 |
TW202428289A (zh) | 2022-11-08 | 2024-07-16 | 美商歐納醫療公司 | 環狀rna組合物 |
WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
WO2024119051A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
WO2024119074A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticle compositions for cell targeting |
WO2024119039A2 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Stealth lipid nanoparticles and uses thereof |
WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
US20240269263A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
WO2024173307A2 (en) | 2023-02-13 | 2024-08-22 | Flagship Pioneering Innovation Vii, Llc | Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions |
WO2024173836A2 (en) | 2023-02-17 | 2024-08-22 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified cytosine |
US20240285805A1 (en) | 2023-02-17 | 2024-08-29 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified uracil |
WO2024192422A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
WO2024192420A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2198931C2 (ru) | 1990-06-11 | 2003-02-20 | Нексстар Фармасьютикалс Инк. | Способ идентификации лигандов, способ получения антитела, способ отбора нуклеиновой кислоты, способ получения смеси нуклеиновых кислот, смесь нуклеиновых кислот, не встречающийся в природе нуклеиново-кислотный лиганд |
GB2270920B (en) | 1992-09-25 | 1997-04-02 | Univ Keele | Alginate-bioactive agent conjugates |
FR2698628B1 (fr) | 1992-12-02 | 1995-02-17 | Fournier Ind & Sante | Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique. |
US5504103A (en) | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
US5777153A (en) | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
AU723163B2 (en) | 1995-06-07 | 2000-08-17 | Tekmira Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
EP0869937A4 (en) | 1995-07-21 | 2004-07-21 | Promega Biosciences Inc | AMID BASED CATIONIC LIPIDS |
JP2001504448A (ja) | 1996-08-30 | 2001-04-03 | フュルステ,イェンス,ペーター | 核酸の鏡面対称選択および進化 |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
CA2217550A1 (en) | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
US6358523B1 (en) | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
AU6949098A (en) | 1997-04-04 | 1998-10-30 | Valentis, Inc. | Improved methods of delivery using cationic lipids and helper lipids |
AU7490098A (en) | 1997-05-15 | 1998-12-08 | Genzyme Corporation | Cationic amphiphile formulations |
PE79099A1 (es) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | Formulaciones de insulina estables |
US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
US20030073640A1 (en) * | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
WO1999004819A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
US6150345A (en) | 1998-08-10 | 2000-11-21 | Regents Of The University Of California | Methods for promoting survival of myelin producing cells |
FR2788275B1 (fr) | 1999-01-11 | 2002-06-14 | Lipha | ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US7015040B2 (en) * | 1999-02-26 | 2006-03-21 | Mirus Bio Corporation | Intravascular delivery of nucleic acid |
AU5173400A (en) | 1999-05-28 | 2000-12-18 | Sugen, Inc. | Protein kinases |
EP1064944A1 (en) | 1999-06-25 | 2001-01-03 | Schering Aktiengesellschaft | Protein kinase N inhibitor comprising Fasudil |
CN1228041C (zh) | 1999-07-15 | 2005-11-23 | 英耐克斯药品股份有限公司 | 脂质包埋的治疗剂的制备方法 |
US6133032A (en) | 1999-09-09 | 2000-10-17 | Isis Pharmaceutical Inc. | Antisense modulation of PI3 kinase p110 beta expression |
CA2404890C (en) | 2000-03-30 | 2013-11-19 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
CA2403962C (en) | 2000-03-31 | 2009-12-15 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability |
EP1355670A2 (en) * | 2000-04-20 | 2003-10-29 | University of British Columbia | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane destabilisers |
AU2002214854A1 (en) | 2000-10-25 | 2002-05-06 | Inex Pharmaceuticals Corporation | Lipid formulations for target delivery |
ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
US20030135033A1 (en) | 2002-01-04 | 2003-07-17 | Anke Klippel-Giese | Compounds and methods for the identification and/ or validation of a target |
AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
US20040156816A1 (en) | 2002-08-06 | 2004-08-12 | David Anderson | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
ATE419865T1 (de) | 2002-08-14 | 2009-01-15 | Silence Therapeutics Ag | Verwendung von protein-kinase-n-beta |
EP1393742A1 (en) | 2002-08-14 | 2004-03-03 | atugen AG | Use of protein kinase N beta |
US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
WO2004058052A2 (en) | 2002-12-20 | 2004-07-15 | Applera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1663171B9 (en) * | 2003-08-26 | 2009-08-19 | SmithKline Beecham Corporation | Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions |
WO2006069782A2 (en) | 2004-12-27 | 2006-07-06 | Silence Therapeutics Ag. | Lipid complexes coated with peg and their use |
WO2005105152A2 (en) | 2004-05-05 | 2005-11-10 | Atugen Ag | Lipids, lipid complexes and use thereof |
WO2006023827A2 (en) | 2004-08-20 | 2006-03-02 | The Johns Hopkins University | Methods for treatment of angiogenesis |
EP1811960A2 (en) | 2004-11-19 | 2007-08-01 | Novosom AG | Improvements in or relating to pharmaceutical compositions for local administration |
WO2006074546A1 (en) | 2005-01-13 | 2006-07-20 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
RU2008145782A (ru) | 2006-04-20 | 2010-05-27 | Сайленс Терапьютикс Аг (De) | Средства для ингибирования экспрессии cd31 |
WO2007121947A1 (en) | 2006-04-20 | 2007-11-01 | Silence Therapeutics Ag. | Lipoplex formulations for specific delivery to vascular endothelium |
RU2553561C2 (ru) | 2006-07-21 | 2015-06-20 | Сайленс Терапьютикс Аг | Средства ингибирования экспрессии протеинкиназы 3 |
-
2005
- 2005-12-27 WO PCT/EP2005/014074 patent/WO2006069782A2/en active Search and Examination
- 2005-12-27 US US11/722,948 patent/US8852472B2/en not_active Expired - Fee Related
- 2005-12-27 EP EP15179144.9A patent/EP2992902A1/en not_active Withdrawn
- 2005-12-27 ES ES05822677.0T patent/ES2548515T3/es active Active
- 2005-12-27 BR BRPI0519468-7A patent/BRPI0519468A2/pt active Search and Examination
- 2005-12-27 DK DK05822677.0T patent/DK1830888T3/en active
- 2005-12-27 SG SG200908620-8A patent/SG158175A1/en unknown
- 2005-12-27 PL PL05822677T patent/PL1830888T3/pl unknown
- 2005-12-27 AU AU2005321469A patent/AU2005321469B2/en not_active Ceased
- 2005-12-27 MX MX2007007913A patent/MX2007007913A/es active IP Right Grant
- 2005-12-27 EP EP05822677.0A patent/EP1830888B1/en not_active Not-in-force
- 2005-12-27 JP JP2007548751A patent/JP5292572B2/ja not_active Expired - Fee Related
- 2005-12-27 KR KR1020077014611A patent/KR101366482B1/ko active IP Right Grant
- 2005-12-27 CN CN2005800450816A patent/CN101287497B/zh not_active Expired - Fee Related
- 2005-12-27 CA CA2593032A patent/CA2593032C/en not_active Expired - Fee Related
-
2007
- 2007-05-22 ZA ZA200704168A patent/ZA200704168B/en unknown
- 2007-06-07 IL IL183775A patent/IL183775A/en not_active IP Right Cessation
-
2008
- 2008-12-05 HK HK08113257.3A patent/HK1119090A1/xx not_active IP Right Cessation
-
2014
- 2014-10-06 US US14/507,045 patent/US9387262B2/en not_active Expired - Fee Related
-
2016
- 2016-09-07 HK HK16110655.7A patent/HK1222541A1/zh unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105873568A (zh) * | 2013-12-05 | 2016-08-17 | 赛伦斯治疗有限公司 | 用于肺特异性递送的工具 |
CN105873568B (zh) * | 2013-12-05 | 2019-10-08 | 赛伦斯治疗有限公司 | 用于肺特异性递送的工具 |
CN105832709A (zh) * | 2016-03-14 | 2016-08-10 | 苏州博创康源生物技术有限公司 | 一种核酸药物载药组织粘贴膜及其制备方法 |
CN105902522A (zh) * | 2016-03-14 | 2016-08-31 | 苏州博创康源生物技术有限公司 | 一种蛋白或多肽药物载药组织粘贴膜及其制备方法 |
CN105902523A (zh) * | 2016-03-14 | 2016-08-31 | 苏州博创康源生物技术有限公司 | 一种载药组织粘贴膜及其制备方法 |
CN106038516A (zh) * | 2016-03-14 | 2016-10-26 | 苏州博创康源生物技术有限公司 | 一种化合物药物载药组织粘贴膜及其制备方法 |
CN106038517A (zh) * | 2016-03-14 | 2016-10-26 | 苏州博创康源生物技术有限公司 | 一种多糖药物载药组织粘贴膜及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2593032C (en) | 2015-12-22 |
SG158175A1 (en) | 2010-01-29 |
HK1119090A1 (en) | 2009-02-27 |
IL183775A (en) | 2016-12-29 |
IL183775A0 (en) | 2007-09-20 |
CN101287497B (zh) | 2013-03-06 |
WO2006069782A9 (en) | 2009-04-30 |
PL1830888T3 (pl) | 2015-12-31 |
KR101366482B1 (ko) | 2014-02-21 |
EP1830888B1 (en) | 2015-08-05 |
JP5292572B2 (ja) | 2013-09-18 |
WO2006069782A3 (en) | 2007-04-12 |
US8852472B2 (en) | 2014-10-07 |
EP2992902A1 (en) | 2016-03-09 |
BRPI0519468A2 (pt) | 2009-01-27 |
HK1222541A1 (zh) | 2017-07-07 |
AU2005321469B2 (en) | 2012-04-05 |
JP2008525514A (ja) | 2008-07-17 |
EP1830888A2 (en) | 2007-09-12 |
ES2548515T3 (es) | 2015-10-19 |
DK1830888T3 (en) | 2015-10-19 |
WO2006069782A2 (en) | 2006-07-06 |
CA2593032A1 (en) | 2006-07-06 |
US20100062967A1 (en) | 2010-03-11 |
MX2007007913A (es) | 2007-08-14 |
US9387262B2 (en) | 2016-07-12 |
KR20070090956A (ko) | 2007-09-06 |
ZA200704168B (en) | 2008-05-28 |
US20150031752A1 (en) | 2015-01-29 |
AU2005321469A1 (en) | 2006-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101287497B (zh) | 涂层脂质复合体和它们的用途 | |
US5851548A (en) | Liposomes containing cationic lipids and vitamin D | |
CN102940891B (zh) | 脂质、脂质复合物及其应用 | |
DE69008521T2 (de) | Kovalente konjugate von lipiden und oligonukleotiden. | |
EP1709195B1 (en) | Cell transfecting formulations of small interfering rna, related compositions and methods of making and use | |
US6011020A (en) | Nucleic acid ligand complexes | |
US5739271A (en) | Thiocationic lipids | |
WO2012083185A2 (en) | Peptide-based in vivo sirna delivery system | |
EP2264167B1 (en) | Double-stranded lipid-modified rna having high rna interference effect | |
CN103380113A (zh) | 含胺的转染试剂及其制备和使用方法 | |
EP2168973A1 (en) | Nucleic acid ligand complexes | |
US5711964A (en) | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D | |
Neuberg et al. | Design and evaluation of ionizable peptide amphiphiles for siRNA delivery | |
EP0747351A2 (en) | Thiocationic lipids, pharmaceutical compositions and methods of use thereof | |
US5759519A (en) | Method for the intracellular delivery of biomolecules using thiocationic lipids | |
US5756352A (en) | Thiocationic lipid-nucleic acid conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1119090 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1119090 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: SILENCE THERAPEUTICS AG Free format text: FORMER NAME: SILENCE THERAPEUTICS AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Berlin Patentee after: SILENCE THERAPEUTICS AG Address before: Berlin Patentee before: Silence Therapeutics AG |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130306 Termination date: 20161227 |
|
CF01 | Termination of patent right due to non-payment of annual fee |